Reogenics - RGX Therapeutics

Platform Guidance Document

A New Therapeutic Architecture for Modern Disease

In today’s landscape of chronic illness, our team has developed a suite of therapeutic solutions designed for intelligent systems-level recalibration—supporting the body in reorganizing its adaptive mechanisms rather than suppressing symptoms.

URL: www.reogenics.com

Platform Overview

Our approach targets foundational physiologic states—including mitochondrial balance, metabolic signaling, neuroimmune modulation, and redox control—using GRAS (Generally Recognized as Safe) ingredients—legally designated (pre-cleared by the FDA for safety in formulation contexts) compounds configured into structured, logic-driven therapeutic stacks.

Each formulation is:

• Multi-pathway in design

• Refined through thousands of reasoning-based modeling iterations across diverse physiologic conditions

• Tested in macro-scale, cyclic cohorts under a controlled logic engine simulating heterogeneous architected states

• Positioned to restore systemic coherence through gentle, non-pharmaceutical biological engagement

This results in an architecture for restorative response—a systems-informed framework that adapts to individual variability while maintaining therapeutic directionality.

Clinical Logic Without the Clinical Risk

Our therapeutic platform occupies a defined niche between conventional supplementation and formal FDA drug pathways. While each formulation is built from GRAS ingredients, the modeling, stacking, and dosing logic elevates these to a level of therapeutic precision typically unseen in the supplement space.

We’ve conducted:

• Thousands of modeled permutations using biological logic engines informed by physiologic-state variability

• Cyclic protocol tests applied across representative virtual and applied subject models (age, metabolic state, co-morbid conditions)

• Real-world scenario testing through supervised application loops (with outcome tracking) that simulate the predictive rigor of preclinical trial phases

These results do not constitute FDA-regulated trials—but they do offer a high-fidelity approximation of clinical effect logic in both outcome trajectory and safety horizon. This hybrid rigor enables prospective licensees to confidently engage prior to clinical filing or consumer-market deployment.

Licensing-Ready Formulations (7)

Each of these has undergone deep systems-based modeling and is ready for clinical, adjunctive, or DTC pathways:

1. RGX-102 Cognilustra™ (NeuroClarity Pediatric Stack)
   Supports early-life neuroimmune and gut-brain axis alignment, mitochondrial function—optimized for ages 6 months to 6 years.

2. RGX-204 Cardisentra™ (Cardiovascular Reset Stack)
   Targets vascular compliance, endothelial resilience, lipid oxidation, and mitochondrial stress without pharmaceutical overlap.

3. RGX-303 Glycorezan™ (Metabolic Recalibration Stack)
   Optimizes hepatic signaling, leptin sensitivity, glucose uptake, and mitochondrial respiration to rebalance metabolic physiology.

4. RGX-404 Filtrexa™ (Renal Optimization Stack)
   Enhances filtration, tubular adaptability, waste clearance, and reduces inflammatory load.

5. RGX-505 Cartisonea™ (Joint Integrity & Structural Restoration)
   Supports cartilage maintenance, synovial fluid biomechanics, and joint stability.

6. RGX-606 Purinivra™ (Uric Acid & Gout Modulation)
   Modulates xanthine oxidase, purine metabolism, and renal purging pathways with redox-balancing nutraceuticals.

7. RGX-707 Oncirestor™ (Adjunctive Oncology Support Protocol)
   Targets the broader physiologic state—angiogenesis, redox environments, and immune scaffolding—to support adjunctive cancer care.

Pipeline Formulations in Development (12)

Building on our architecture for restorative response, these advanced stacks are currently in systems-modeling refinement:

• RGX-808 Virethalon™ (Men’s Hormonal Integrity)

• RGX-909 Estrogenova™ (Women’s Perimenopausal Modulator)

• RGX-010 Autoimmunexa™ (Autoimmune Re-patterning for RA/Lupus)

• RGX-111 Virosentinel™ (Post-viral & Long Covid Physiological State Modulator)

• RGX-121 Neuroadapta™ (Neuroadaptive Recovery)

• RGX-131 Symbiotral™ (Gut-Brain Axis Stabilizer)

• RGX-141 Neuratherix™ (Non-stimulant Cognitive Edge)

• RGX-151 Mycotoxica™ (Mycotoxin Clearance Facilitator)

• RGX-161 Histarecover™ (Allergy & Histamine Balance)

• RGX-171 Tensyra™ (Tendon/Ligament Cellular Support)

• RGX-181 Visiorene™ (Ocular Regeneration Stack)

• RGX-191 Growthalign™ (Pediatric Developmental Support)

Each module is structured within a systems-modeling paradigm that privileges emergent, adaptive physiologic outcomes over simple symptom override.

Why It Matters

• Positioned for Regulatory Flexibility: Operates within a regulatory-safe GRAS structure (pre-cleared by the FDA for safety in formulation contexts) while offering modeled clinical logic.

• Licensable & Brand-Ready: Distinct RGX codes and coined stack names are trademarked™ under applied use and structured for registration.

• Backed by High-Volume, Systems-Level Modeling
  Our protocols are not based on speculation or anecdote. They are the result of over 50,000 modeled biological system cycles, each simulating multi-pathway responses across metabolic, neuroimmune, mitochondrial, and detoxification networks. This quantitative foundation allows us to forecast efficacy and safety profiles with precision—long before clinical deployment.

• Built for Scale: A coherent platform, not isolated formulations—engineered to grow across verticals.

Regulatory Foresight & IP Status

Each therapeutic formulation within the RGX suite is:

• Protected under active trademark designation through applied commercial use, with structured brand registration planned.

• Built on FDA-compatible logic—with structured clinical protocols and safety modeling frameworks developed in advance to accelerate clinical trial preparation.

• Positioned for hybrid-market use—deployable in wellness, practitioner-grade, or investigational contexts, depending on application strategy.

This means licensing partners gain access to formulation logic and future trial readiness without waiting for regulatory approvals—yet with clear optionality to pursue them under a joint or exclusive framework.

Next Steps

If your organization seeks access to a differentiated therapeutic platform grounded in precision logic, bio-alignment, and structured integration, we invite confidential discussion. Exclusive and shared licensable models are available.

Request a private briefing through our intake portal to begin. contact@ipboardwalk.com